Rock Springs Capital Management LP Atreca, Inc. Transaction History

Rock Springs Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.78 - $1.68 $78,000 - $168,000	-100,000 Reduced 21.62%	362,530 $290,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $7,749 - $16,983	2,700 Added 0.59%	462,530 $1.4 Million
Q2 2021 Aug 16, 2021	BUY	$7.82 - $13.8 $46,138 - $81,420	5,900 Added 1.3%	459,830 $3.92 Million
Q1 2021 May 17, 2021	BUY	$13.0 - $19.34 $35,100 - $52,218	2,700 Added 0.6%	453,930 $6.96 Million
Q4 2020 Feb 16, 2021	BUY	$13.03 - $17.09 $5,212 - $6,836	400 Added 0.09%	451,230 $7.29 Million
Q3 2020 Nov 16, 2020	BUY	$12.67 - $23.19 $5.71 Million - $10.5 Million	450,830 New	450,830 $6.3 Million

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.